Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis. - Wikidata - wikimedia - TriplyDB

Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

http://www.wikidata.org/entity/Q37015471

about

Diagnosis of Tensilon-Negative Ocular Myasthenia Gravis By Daily Selfie Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica.Factors affecting outcome in ocular myasthenia gravis.Low conversion rate of ocular to generalized myasthenia gravis in Singapore.Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China.

P2860

Q42364275-3CA0C190-4C39-44C8-9C15-793DE6CBD729 Q47192132-89CA7421-59C4-4080-83F2-FA94D7AC30FB Q47690888-8440B109-792E-4992-8D77-1EF36DCEA598 Q49582626-BB5488F5-AB22-4B40-90E7-D96BEDDAB9D1 Q52657186-EAC7752F-B63E-495E-A206-550B7989386C

P2860

Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

http://www.wikidata.org/entity/Q37015471

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 August 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

@en

Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

@nl

type

label

Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

@en

Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

@nl

prefLabel

Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

@en

Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

@nl

P1433

Q37015471-214FABF4-813C-4173-8EE1-2A23EEC420FE

P1476

Q37015471-1E21477B-C019-402C-B009-F4DE5D500A92

P2093

Q37015471-2034644B-D68C-4D98-A3EE-59B1D6D8CE14

Q37015471-44C2BB9F-F4E6-4BF3-995D-A182709916CD

Q37015471-937F3D72-EA49-4C38-857C-A307C402D0BC

P2860

Q37015471-408BE2CD-FBBC-4B05-9BD8-B7C22112B341

Q37015471-45389707-0559-475A-BE16-B2E8146A28C4

Q37015471-59F20AA5-93CF-44AF-AFB6-7C27F2C0C012

Q37015471-8AA61F4F-BAB9-4A84-9718-6BE4FC6B7BFF

Q37015471-A88D1603-BC8B-4AF8-B1E2-55F2189A08EE

Q37015471-A92385D8-E0EA-4807-92D4-BDCE789D734D

Q37015471-B6CF37F2-4BE3-42AD-8CF9-2429BA55A4CC

Q37015471-B81998A4-2121-469E-8D12-2E702FCACFAB

Q37015471-C0461253-D11A-4E53-9139-B8224F9A97E0

Q37015471-CBEE33D3-3E57-4B1E-830B-6F91881D8024

P304

Q37015471-1D7D07E2-9F79-423C-98CA-9EEC3E077BA2

P31

Q37015471-B1966F00-2748-48C0-88B2-8A9906351C7E

P356

Q37015471-C182F865-CE1E-48FF-8A30-E3C3C02C5BF2

P407

Q37015471-A71831D8-4E1D-44EA-BA8E-07DFFD6E1433

P433

Q37015471-C119F542-CD99-4DFB-9414-7466A1DCC083

P478

Q37015471-8562601E-A180-48F8-9D66-7211A206CD44

P50

Q37015471-646DE17F-E1E8-442B-86FA-87C11AB4FE6E

Q37015471-B97DFB45-1C21-42B4-A3B8-4D8F7B46A895

Q37015471-DCDD5ED5-5ACD-421D-B566-D2A11A7B57B9

Q37015471-ED8F3F37-E8C6-428F-8165-1DB0D1FB7A72

P577

Q37015471-3E748DB8-D089-4965-9A8B-150C69BE1A0D

P698

Q37015471-5E03B4BB-555C-42AF-B177-9EA2EF571F6E

P921

Q37015471-CF8ED99C-98DB-4A82-9BC3-35BC8F43783A

P932

Q37015471-0AD828D3-CFE8-4A2F-8E7A-CEE63FA8BA4D

P356

JAMANEUROL.2015.1444

P1433

P1476

Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis

@en

P2093

Eric R Eggenberger

http://www.w3.org/2001/XMLSchema#string

Lina Nagia

http://www.w3.org/2001/XMLSchema#string

Wayne T Cornblath

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical implementation of anti-acetylcholine receptor antibodies.

Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.

Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.

A systematic review of diagnostic studies in myasthenia gravis.

Ocular myasthenia: diagnostic value of single fibre EMG in the orbicularis oculi muscle.

Lifetime course of myasthenia gravis.

EFNS/ENS Guidelines for the treatment of ocular myasthenia.

The course of myasthenia gravis and therapies affecting outcome.

Development of generalized disease at 2 years in patients with ocular myasthenia gravis.

Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?

P304

1170-1174

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMANEUROL.2015.1444

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

Lindsey B De Lott

Crandall Peeler

Lindsey B DeLott

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26258604

http://www.w3.org/2001/XMLSchema#string

P921

myasthenia gravis

P932

4911808

http://www.w3.org/2001/XMLSchema#string